---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-25-000103"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:14:27.289723+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Neurogene Q3 2025: $21M net loss; NGN-401 gene therapy shows 35 skill acquisitions, registrational trial started

## Summary
- Net loss of $21.0M for Q3 2025 vs $20.2M in Q3 2024; R&D expenses $17.2M, G&A $6.6M.
- Positive interim Phase 1/2 data: 35 developmental milestones/skills acquired across 8 pediatric participants; durable CGI-I gains.
- First participant dosed in Embolden registrational trial for Rett syndrome; enrollment expected in 3-6 months.
- Cash, equivalents, investments of $265.4M as of Sep 30, 2025; runway through Q1 2028.
- Preclinical data showed ICV delivery superior to IT-L for AAV biodistribution in key brain regions.

## SEC filing metadata
- accession: 0001404644-25-000103
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000103/0001404644-25-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000103/ngne-20251113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-25-000103
- JSON: https://secwatch.observer/filing/0001404644-25-000103.json
- Plain text: https://secwatch.observer/filing/0001404644-25-000103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.